Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Clinical trial NCT02821000 · COMPLETED
Trial details
- NCT number
- NCT02821000
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-08
- Primary completion
- 2017-12-27
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.